U.S. markets open in 3 hours 12 minutes

Fulgent Genetics, Inc. (FLGT)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
56.71+3.08 (+5.74%)
Al cierre: 04:00PM EDT
56.88 +0.17 (+0.30%)
Fuera de horario: 07:08PM EDT

Fulgent Genetics, Inc.

4978 Santa Anita Avenue
Temple City, CA 91780
United States
626 350 0537
https://www.fulgentgenetics.com

Sector(es)Healthcare
IndustriaDiagnostics & Research
Empleados a tiempo completo645

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Ming HsiehChairman, CEO & Pres5.66MN/D1956
Mr. Paul KimChief Financial Officer669.98kN/D1967
Mr. Jian XieChief Operating Officer704.62kN/D1966
Dr. Han Lin Gao D.A.B.M.G., F.A.C.M.G., FACMG, M.D., Ph.D.Chief Scientific Officer & Laboratory Director630.54kN/D1967
Mr. Brandon PerthuisChief Commercial OfficerN/DN/DN/D
Dr. Lawrence M. Weiss M.D.Chief Medical OfficerN/DN/D1957
Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Gestión corporativa

La calificación ISS Governance QuickScore de Fulgent Genetics, Inc. a partir del 1 de mayo de 2022 es 7. Las puntuaciones principales son Auditoría: 5; Junta: 7; Derechos del accionista: 4; Compensación: 9.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.